Mr. Leo joined the private equity team at HBM Partners in 2007. He has been responsible for investments in over 20 private biotech, medical device and diagnostics companies in the United States and Europe, in most cases as a board member or board observer. These companies have so far generated seven NASDAQ IPOs, five M&A transactions, and five FDA-approved marketed products. In addition to serving as a director on Fore’s board, He currently serves on the boards of Galecto, Gynesonics and Monte Rosa Therapeutics.
Prior to joining HBM, Mr. Leo worked as a postdoctoral scientist at Stanford University, as a physician at the University Hospital Leipzig and as a principal at Wellington Partners Venture Capital. He earned an M.D. from the Freie Universität Berlin (Charité), an M.A.S. in Medicines Development from the University of Basel and an MBA with distinction from INSEAD.
